Drug Discovery World

MARCH 25, 2024

Allogene Therapeutics and Arbor Biotechnologies Biotechnology companies Allogene Therapeutics and Arbor Biotechnologies entered a non-exclusive, global gene editing licensing agreement for use of Arbor’s proprietary CRISPR gene-editing technology in Allogene’s AlloCAR T platform for the treatment of autoimmune disease (AID).

Drugs 130

Drugs Licensing Licensing Laboratories 130

Codon

AUGUST 26, 2024

Brian Wang (co-founder of the nonprofit Panoplia Laboratories ) outlines his approach to making broad-spectrum antivirals. When COVID-19 emerged in 2019, by contrast, mRNA vaccines developed by Pfizer and Moderna took just 326 days from the initial sequencing of the virus to gaining approval for emergency use.

RNA 87

RNA Virus DNA Vaccine 87

Drug Discovery World

JUNE 6, 2024

Professor Charles Swanton, Cancer Research UK’s chief clinician, said the melanoma trial results were “extremely impressive”, adding: “The new vaccine approach is another piece of the puzzle that will allow more patients to be cured, hopefully, or fewer patients to suffer disease relapse. The follow-up of the Phase IIb study took place 34.9

Vaccine 147

Vaccine Clinical Trials FDA Approval Research Laboratories 147

Drug Discovery World

DECEMBER 18, 2023

An effective HIV vaccine may need to prompt strong responses from CD8+ T cells to protect people from acquiring HIV, according to a study from the National Institute of Allergy and Infectious Diseases (NIAID).

Vaccine 147

Vaccine Clinical Trials Laboratories Virus 147

The Pharma Data

AUGUST 3, 2021

The drug, which has undergone several clinical trials for human conditions but has not yet received approval to treat humans, inhibited the replication of SARS-CoV-2, the virus that causes COVID-19, in human cell cultures and in a mouse model, leading to much lower viral loads. The research team, including scientists from the U.S.

Virus 52

Virus Clinical Trials Drugs Laboratories 52

Drug Discovery World

MAY 29, 2023

The US Food and Drug Administration has approved Krystal Biotech’s Vyjuvek, a herpes-simplex virus type 1 (HSV-1) vector-based gene therapy, for the treatment of dystrophic epidermolysis bullosa (DEB). DEB is a genetic disorder that affects the connective tissue in the skin and nails and results from mutation(s) in the COL7A1 gene.

FDA Approval 130

FDA Approval Therapies FDA Virus 130

Drug Discovery World

NOVEMBER 1, 2022

Such disorders include neurodegenerative diseases that affect the brain, including Alzheimer’s disease, forms of blindness and some cancers. . Therapies that don’t precisely target diseased cells can have unintended effects in other healthy cells.” . Splicing-linked expression design. Initial success in the lab.

Packaging 130

Packaging RNA Laboratories Therapies 130

Drug Discovery World

DECEMBER 6, 2023

This will allow us to tackle a range of bacterial diseases and react quickly to global health needs, including potential future pandemics.” Current estimates suggest that antibiotic-resistant bacteria could claim 10 million lives per year by 2050.

Laboratories 130

Laboratories Virus Science Disease 130

Drug Discovery World

NOVEMBER 30, 2022

million to support further development of the re-engineered technology for use in the global response to future disease outbreaks. . The Coalition for Epidemic Preparedness Innovation (CEPI) has committed up to AU$8.5 ($5.7)

Vaccine 130

Vaccine Immune Response Virus Engineering 130

BMG Labtech

MARCH 11, 2024

Enzyme-Linked Immunosorbent Assays (ELISAs) are an essential technique in today’s laboratory with many applications in the life sciences. 1,2 Anton Schuurs and Bauke van Weemen at the research laboratories of NV Organon, Oss, the Netherlands developed a similar technique which was also published in 1971.

Vaccine 98

Vaccine Molecular Biology Laboratories Virus 98

Broad Institute

APRIL 25, 2024

He started to imagine how the deadly and contagious disease, if confirmed, might spread to half the city’s population. Eight of the 20 patients died, but the spread of the disease in Nigeria stopped there. Blood and urine samples from the man were waiting for Happi in his lab. Happi felt chilled. They called the idea Sentinel.

Virus 132

Virus Hospitals Disease Government 132

SCIENMAG: Medicine & Health

OCTOBER 18, 2023

This study is conducted by the Jiangsu Provincial Center for Disease Control and Prevention, National Institute of Diagnostics and Vaccine Development in Infectious Diseases, State Key Laboratory of Vaccines for Infectious Diseases of Xiamen University, China National Institutes for Food and Drug Control, and Xiamen Innovax Biotech Company.

Vaccine 52

Vaccine Laboratories Virus Science 52

PerkinElmer

MAY 28, 2020

Time is of the essence when it comes to the development of a vaccine for the novel infectious disease in our current pandemic. Unfortunately, the road towards treatment can be time-consuming, especially when utilizing assays with live virus.

Vaccine 52

Vaccine Disease Virus Small Molecule 52

Drug Discovery World

JUNE 7, 2023

McCarthy said: “At pHion Therapeutics, it is our mission to pioneer next generation, first-in-class vaccines for infectious disease and oncology through stealth-like delivery of mRNA. Infection with HPV is responsible for approximately 90% of cervical cancers and up to 70% of oropharyngeal cancers, with a high unmet clinical need.

Vaccine 130

Vaccine Testimonials Clinical Trials Laboratories 130

Drug Discovery World

DECEMBER 14, 2023

The new centre represents a flagship investment within the University’s Glasgow Riverside Innovation District (GRID) and will be home to commercial businesses as well as the University of Glasgow-led Living Laboratory for Precision Medicine.

Drugs 189

Drugs Science Research Laboratories 189

Drug Discovery World

FEBRUARY 6, 2024

From finding potential active substances and identifying novel targets, to simulating how drugs will function in the human body and optimising laboratory workflows, digital technologies are having a significant impact on drug discovery and development. Obulytix is not alone.

Marketing 173

Marketing Laboratories Engineering Clinical Trials 173

Drug Discovery World

AUGUST 21, 2024

Cell and gene therapies have revolutionised how clinicians treat a variety of diseases including cancer, blindness, and metabolic disorders. With these therapies, genes can be delivered into cells to replace defective alleles or produce new functional proteins to treat or cure disease.

Therapies 147

Therapies Bioinformatics DNA FDA 147

The Pharma Data

JANUARY 6, 2021

A Novel Ebola Virus VP40 Matrix Protein-Based Screening for Identification of Novel Candidate Medical Countermeasures.’ sangivamycin) has broad-spectrum antiviral activity in laboratory-based assays against several viruses. ROCHESTER, N.Y. , 7, 2021 /PRNewswire/ — OyaGen, Inc. Bennett et al., About OYA1. OYA1 (a.k.a.

Virus 40

Virus Clinical Trials Government Laboratories 40

The Pharma Data

DECEMBER 25, 2020

While early data suggests that these new variants may be more transmissible, to date there is no evidence that they cause more severe disease or have any impact on antibody response or vaccine effectiveness. The best way to prevent infection with any variant of COVID-19 is to follow public health measures.

Virus 52

Virus Compliance Government Laboratories 52

Drug Discovery World

DECEMBER 6, 2022

The team combined scientists from Scripps Research, IAVI, Fred Hutchinson Cancer Center (Fred Hutch) and the National Institutes of Health, National Institute of Allergy and Infectious Diseases (NIAID) Vaccine Research Center (VRC). . The researchers used ‘germline targeting’ to produce bnAbs that can protect against HIV.

Vaccine 130

Vaccine Trials Clinical Trials Virus 130

The Pharma Data

SEPTEMBER 1, 2021

Study Now Enrolling Participants Who Live in the Same Household as Someone With Symptomatic, Laboratory-Confirmed COVID-19. The global study is enrolling individuals who are at least 18 years of age and reside in the same household as someone with laboratory-confirmed SARS-CoV-2 infection with symptoms. MOVe-AHEAD Study.

Laboratories 52

Laboratories Virus Clinical Trials Research Laboratories 52

Drug Discovery World

SEPTEMBER 20, 2022

Breakthroughs in gene therapy are only possible with an exact understanding of the genetic underpinnings of disease. Long-reads are often applied in complex areas, such as rare diseases and neurodegenerative diseases, which require deeper insights into more regions of the human genome that cannot be achieved with short read alone. .

Therapies 130

Therapies DNA Disease Research 130

Broad Institute

AUGUST 31, 2023

Related News Next generation prime editing systems move closer to possible therapeutic applications New CRISPR genome editing system offers a wide range of versatility in human cells Prime editing technologies allow scientists to precisely edit the genome in a variety of ways and could one day be used to treat genetic diseases.

DNA 145

DNA Engineering RNA Laboratories 145

Drug Target Review

JANUARY 26, 2024

Researchers from Columbia University and the US Department of Energy (DOE)’s Brookhaven National Laboratory have elucidated a method to produce large quantities of the receptor that the SARS-CoV-2 spike protein uses to bind to the surface of human cells.

Production 114

Production DNA Virus Protein Expression 114

DrugBank

JULY 18, 2024

Vaccines have consistently demonstrated their efficacy in protecting people from infectious diseases. This led to the eradication of smallpox and polio – two debilitating diseases that historically caused global epidemics. Let’s take a deeper dive into these challenges.

Vaccine 79

Vaccine Immune Response Clinical Trials Virus 79

The Pharma Data

APRIL 22, 2023

Such a vaccine may provide long-lasting immunity against future emerging variants and could be used as a model for other seasonal viral diseases like the flu. This research also paves the way for the potential rapid design of novel T-cell vaccines against emerging and seasonal viral diseases, like influenza.”

Vaccine 40

Vaccine Virus Laboratories Immune Response 40

The Pharma Data

OCTOBER 28, 2020

In the overall patient group with detectable virus at baseline, the average daily reduction in viral load through day 7 was a 0.36 About REGN-COV2 REGN-COV2 is a combination of two monoclonal antibodies (REGN10933 and REGN10987) and was designed specifically to block infectivity of SARS-CoV-2, the virus that causes COVID-19.

Virus 40

Virus Trials Clinical Trials Production 40

Drug Target Review

SEPTEMBER 4, 2023

There have been several studies that have reported the ability of infectious disease agents to be drug resistant. Infectious agent includes bacteria, virus, fungi, and parasites, and they are capable of causing disease in a living organism. 7,13 The use of Plants extract is important in drug discovery.

Drugs 111

Drugs RNA DNA Disease 111

Broad Institute

JUNE 27, 2024

Science (2024) Related content New gene delivery vehicle shows promise for human brain gene therapy My Quest to Cure Prion Disease — Before It’s Too Late | Sonia Vallabh | TED Prion diseases lead to rapid neurodegeneration and death and are caused by misshapen versions of the prion protein in the brain.

Disease 142

Disease Therapies Engineering Clinical Trials 142

The Pharma Data

MARCH 8, 2021

The companies today reported findings on one secondary objective from the Phase 2a study, showing a reduction in time (days) to negativity of infectious virus isolation in nasopharyngeal swabs from participants with symptomatic SARS-CoV-2 infection, as determined by isolation in Vero cell line culture. About Molnupiravir.

Trials 69

Trials Virus RNA Research Laboratories 69

The Pharma Data

DECEMBER 10, 2020

The FDA said Thursday that it has developed a test for COVID-19 in fecal matter, in an attempt to prevent the disease from being inadvertently transmitted during fecal transplantation. We know now that the viral RNA is found in stool and infectious virus as well. 1, 2019, until effective screening methods are implemented.”.

FDA 52

FDA Laboratories RNA Virus 52

Alta Sciences

MARCH 1, 2024

Norbert Makori and Pierre Jolicoeur: The Benefits of Combining Preclinical and Bioanalytical for Your Gene Therapy Studies pmjackson Fri, 03/01/2024 - 22:20 Recent advances in gene therapy have allowed for diseases to be approached differently. Gene therapy was first discovered in the 1960s, but only gained commercial interest in the 1980s.

Therapies 52

Therapies Laboratories Molecular Biology RNA 52

NIH Director's Blog: Drug Development

MAY 21, 2020

B38 blocks SARS-CoV-2 from binding to the ACE2 receptor (light pink) of a human cell, ACE2 is what the virus uses to infect cells. The research team, led by Yan Wu, Capital Medical University, Beijing, first isolated the pair of antibodies in the laboratory, starting with white blood cells from the patient.

Virus 52

Virus Vaccine Laboratories Small Molecule 52

The Pharma Data

JULY 12, 2021

The data were presented during the late-breaking clinical trials session at the European Congress of Clinical Microbiology & Infectious Diseases (ECCMID). Headquartered in Miami, Florida, Ridgeback Biotherapeutics LP is a biotechnology company focused on emerging infectious diseases. About Molnupiravir. Source link: [link].

Clinical Trials 52

Clinical Trials Laboratories Research Laboratories Hospitals 52

The Pharma Data

JANUARY 15, 2021

16, 2021 /CNW/ – As the resurgence of COVID-19 activity continues in Canada , we are tracking a range of epidemiological indicators to monitor where the disease is most active, where it is spreading and how it is impacting the health of Canadians and public health , laboratory and healthcare capacity. OTTAWA, ON , Jan.

Virus 52

Virus Laboratories Hospitals Vaccine 52

The Pharma Data

NOVEMBER 29, 2021

1.1.529 a variant of concern, named Omicron, on the advice of WHO’s Technical Advisory Group on Virus Evolution (TAG-VE). Severity of disease : It is not yet clear whether infection with Omicron causes more severe disease compared to infections with other variants, including Delta. Studies underway.

Vaccine 52

Vaccine Virus Hospitals Disease 52

Drug Discovery World

OCTOBER 13, 2022

Combining the company’s technology with intelligent software, the STAR enables reliable and safe liquid handling performance, which leads to trustworthy results and lower routine laboratory costs. . Hub Organoids presented several posters which highlighted the diverse capabilities of Hub Organoids in optimising various treatment regimens.

Drugs 130

Drugs Cell Based Assays Science Assay Development 130